Serum Institute of India (SII) has prepared 4 crore does Covid-19 vaccines. The company said in a release, “SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling license from DCGI.”
The Indian Council of Medical Research (ICMR) with the help of SII will pursue the early availability of this product for India.
According to earlier reports, Serum Institute CEO Adar Poonawalla said that a vaccine against the coronavirus disease is likely to be available in the country by January 2021 provided approvals from regulatory bodies are in place in time.
SII has announced the completion of enrolment of Phase III clinical trials for COVISHIELD vaccine in India, under the partnership of Serum Institute of India and Indian Council of Medical Research (ICMR).
Read To Know More – https://t.co/0NrpTjjOXx pic.twitter.com/apI5T9DroD
— SerumInstituteIndia (@SerumInstIndia) November 12, 2020
“Based on the success of the trials in India and the United Kingdom, and if approvals from regulatory bodies are in place in time, then we can expect the vaccine to be available in India by January 2021, only if it’s proven immunogenic and efficacious.” Poonawalla had said.
The completion of enrolment of phase-3 trials for the novel coronavirus vaccine-Covishield-in India has been announced by SII and ICMR. At present, SII and ICMR are conducting Phase 2/3 clinical trial of Covishield at 15 different centres, across the country.
The SII Pune laboratory has developed Covishield, with a master seed from Oxford University/Astra Zeneca. The vaccine made in UK is currently being tested in large efficacy trials in UK, Brazil, South Africa and USA.
Meanwhile, according to the Union Health Ministry data India’s Covid-19 caseload climbed to 86,83,916. The coronavirus death toll has reached to 1,28,121, while the number of people who have recuperated from the disease have surged to 80,66,501. The number of active cases remained below 5 lakh for the second consecutive day.
